Discovery
Medicinal Chemistry Services
Discovery ADME
- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
›
›
›
›
›
›
›
white-paper
The US Food and Drug Administration (FDA) issued new draft guidance in December 2016 indicating that generic manufacturers can demonstrate bioequivalence for a specific semi-solid dosage form using predictive in vitro testing as a surrogate for in vivo testing. In this paper, we explain how bioequivalence can be achieved for generics in semi-solid dosage forms, including the role of in vitro release testing (IVRT) and in vitro permeation testing (IVPT).
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Accept Privacy Policy